Evidence map›Paper›PMID 36795122›Full record

ArticleCancer immunology, immunotherapy : CII2023

Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy.

Mingjia Li, Songzhu Zhao, Gabrielle Lopez, Austin Secor, Parthib Das, Nitya Surya, Madison Grogan, Sandip Patel, Karthik Chakravarthy, Abdul Miah and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. TEP RNA: a new frontier for early diagnosis of NSCLC.Journal of cancer research and clinical oncology · 2024
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 1 institution in 1 country.

Mingjia LiDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA. Mingjia.Li@OSUMC.EDU.ORCID http://orcid.org/0000-0002-3910-4179
Songzhu ZhaoDepartment of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, USA.
Gabrielle LopezDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Austin SecorCollege of Medicine, The Ohio State University, Columbus, USA.
Parthib DasDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Nitya SuryaCollege of Medicine, The Ohio State University, Columbus, USA.
Madison GroganDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Sandip PatelDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Karthik ChakravarthyCollege of Medicine Medical Scientist Training Program, The Ohio State University, Columbus, USA.
Abdul MiahDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Daniel SpakowiczDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Gabriel TinocoDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Zihai LiDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Lai WeiDepartment of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, USA.
Kai HeDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Erin BertinoDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Asrar AlahmadiDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Regan MemmottDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Jacob KaufmanDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Peter G ShieldsDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
David P CarboneDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Carolyn J PresleyDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Gregory A OttersonDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Dwight H OwenDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.ORCID http://orcid.org/0000-0002-6598-4886
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
The microbiome in older adults with lung cancer: association of treatment regimens and diet with protective microbial profilesK01AG070310 · NIA · OHIO STATE UNIVERSITY · PI SPAKOWICZ, DANIEL J. · 2021 to 2025
$583k
NCATS NIH HHS UL1 TR002733NCI NIH HHS P30 CA016058NIA NIH HHS K01 AG070310NIH HHS P30CA016058
6 · The paper itself

Abstract

introductionPatients treated with immune checkpoint inhibitors (ICIs) may not response to treatment and are at risk for immune-related adverse events (irAEs). Platelet function has been linked to both oncogenesis and immune evasion. We studied the association between the change in mean platelet volume (MPV), platelet count, survival, and the risk of developing irAEs in patients with metastatic non-small cell lung cancer (NSCLC) who have received first-line ICI.

methodsIn this retrospective study, delta (∆) MPV was defined as the difference between cycle 2 and baseline MPV. Patient data were collected via chart review, and Cox proportional hazard and Kaplan-Meier method were used to assess the risk and estimate median overall survival.

resultsWe identified 188 patients treated with first-line pembrolizumab, with or without concurrent chemotherapy. There were 80 (42.6%) patients received pembrolizumab monotherapy, and 108 (57.4%) received pembrolizumab in combination with platinum-based chemotherapy. Patients whose MPV (∆MPV ≤ 0) decreased had hazard ratio (HR) = 0.64 (95% CI 0.43-0.94) for death with p = 0.023. Patients with ∆MPV ≤ - 0.2 fL (median), there was a 58% increase in the risk of developing irAE (HR = 1.58, 95% CI 1.04-2.40, p = 0.031). Thrombocytosis at baseline and cycle 2 was associated with shorter OS with p = 0.014 and 0.039, respectively.

conclusionChange in MPV after 1 cycle of pembrolizumab-based treatment was significantly associated with overall survival as well as the occurrence of irAEs in patients with metastatic NSCLC in the first-line setting. In addition, thrombocytosis was associated with poor survival.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsThrombocytosisAntibodies, Monoclonal, HumanizedHumansMean Platelet VolumeRetrospective StudiesAntibodies, Monoclonal, HumanizedpembrolizumabImmune-related adverse eventsImmunotherapyMean platelet volumeNon-small cell lung cancerOverall survivalPlatelets

Identifiers

PMID36795122
PMCPMC10991400
OpenAlexW4321003615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.